Zoetis Q3 Revenue Slips on Competition, But EPS Guidance Raised

What happened

Zoetis reported lower third-quarter revenue as increased competition and softer veterinary visit trends pressured its companion animal segment, while livestock and diagnostics units provided some offset. Management narrowed full-year revenue guidance to the high end of its previous range, signaling a slightly better-than-feared top-line outcome for fiscal 2026. The company raised its adjusted earnings guidance, reflecting strong cost discipline and margin resilience despite the revenue shortfall. This dynamic mirrors the prior year's pattern where top-line growth stalled but EPS was protected through expense management. The stock's reaction will hinge on whether investors view the EPS beat as sustainable or as a short-term band-aid masking deteriorating organic growth.

Implication

Investors should monitor competitive dynamics in companion animal health and the trajectory of OA mAb sales, as continued revenue declines could erode the premium multiple. However, the raised EPS guidance underscores management's ability to protect profitability through cost discipline, providing a floor for the stock. The base scenario of modest growth remains intact, but a sustained top-line slowdown would push the bear case probability higher. We maintain a wait stance, with attractive entry near $110 and trim above $150, as the risk-reward is balanced but not compelling.

Thesis delta

The new Q3 data reinforce the thesis that Zoetis's top-line growth remains challenged by competition and soft demand, but management's cost control is effectively shielding earnings. This slightly increases the probability of the bear case if revenue declines persist, while reducing the likelihood of the bull case in the near term. The overall investment thesis is unchanged: a wait-and-see approach until clearer evidence of organic growth reacceleration emerges.